Early‐Onset Gastric Cancer as a High‐Risk Disease Entity in the United States: Clinicopathologic Features, Regional Variation, and Outcomes Authors: Dani R. Castillo, Pranati Shah, Derek Tai, Mengni Guo, Max Hazeltine, Sofia Guzman, Daniel Park, Rifat Mannan, Yan Xing, Gagandeep Brar, Mustafa Raoof, Cathy Eng, Shengyang Wu Published: 2026 ABSTRACT ABSTRACTIntroductionEarly‐onset gastric cancer (EOGC), defined as diagnosis before age 45, represents a distinct and increasingly recognized subset of gastric cancer. Emerging evidence suggests that clinical behavior, treatment patterns, and outcomes differ from average‐onset disease, yet these differences remain incompletely characterized. We evaluated demographic, geographic, pathologic, treatment, and survival patterns in patients with EOGC.MethodsThis retrospective cohort study included patients with stage II–III gastric cancer diagnosed between 2006 and 2022 who underwent curative‐intent gastrectomy in the National Cancer Database (NCDB). EOGC was defined as age ≤ 45 years at diagnosis. Demographic, pathologic, and treatment variables were analyzed. Overall survival (OS) was estimated using Kaplan–Meier methods and Cox proportional hazards models. A landmark analysis excluding patients with < 6 months of follow‐up addressed survivorship bias.ResultsAcross nearly two decades, EOGC accounted for 7.3% of the cohort and demonstrated demographic and geographic concentration, particularly among Hispanic, Black, and Asian patients. EOGC was associated with aggressive clinicopathologic features, including diffuse or signet‐ring histology, poor differentiation, and advanced nodal disease. Although patients with EOGC more frequently received perioperative or neoadjuvant chemotherapy compared with older cohorts, pathologic complete response rates remained low, underscoring limited benefit from treatment intensification alone.ConclusionsDespite receipt of more intensive multimodality therapy, EOGC did not demonstrate superior survival outcomes. These findings highlight EOGC as a clinically distinct, high‐risk disease subtype and support the need for biomarker‐driven therapeutic strategies and earlier detection efforts in high‐risk populations. Introduction Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancer‐related death worldwide [1]. Major risk factors for GC include Helicobacter pylori infection, high salt intake, low‐fiber diet, Epstein–Barr virus infection, and tobacco use. Risk also increases with older age, and their prevalence and impact vary by region [2, 3, 4]. While there is no universally accepted age cutoff for early‐onset GC (EOGC), studies have proposed thresholds ranging from 30 to 50 years, with more recent literature commonly adopting 40 years or 45 years old [3, 5, 6, 7]. Global incidence of EOGC has generally declined over the past three decades, but with regional heterogeneity and persistent incidence among younger adults [8, 9]. Although GC predominantly affects individuals aged 50–70 years and its overall incidence has declined over the past decade [10], Given that different age cutoffs may impact survival analyses, we used ≤ 45 years as the threshold for EOGC in this study to better characterize its distinct clinicopathologic features and outcomes. EOGC is enriched for Epstein–Barr virus (EBV)–positive and genomically stable (GS) molecular subtypes, which are closely associated with diffuse and signet‐ring histology, CDH1/RHOA alterations, and limited chromosomal instability [11, 12], distinguishing EOGC from that observed in later‐onset patients. The influence of age‐related treatment patterns on survival remains unclear. To address this gap, we performed a retrospective cohort study to characterize the clinicopathologic features, treatment patterns, and survival outcomes of this patient population. Materials and Methods Data This retrospective cohort study used data from the National Cancer Database (NCDB), a hospital‐based registry of cancer outcomes established collaboratively by the American Cancer Society and the American College of Surgeons Commission on Cancer (CoC). The NCDB aggregates data from a wide array of sources, including teaching hospitals, community cancer centers, and Veterans Affairs hospitals across 50 US states and Puerto Rico. Participation in reporting to the NCDB is restricted to CoC‐approved hospitals, which capture an estimated 70% of all new cancer diagnoses in the US [13, 14]. The NCDB Participant User Data File (PUF), a Health Insurance Portability and Accountability Act–compliant repository of de‐identified patient‐level data, served as the primary dataset for this analysis. Given the de‐identification of patient information in the Participant User Data File, this analysis was exempt from institutional review board approval. This study was conducted in accordance with 45 CFR §46 guidelines. We adhered to the Strengthening Reporting of Observational Studies in Epidemiology (STROBE) guidelines [15]. Cohort This retrospective cohort study included patients with pathologic stage II–III GC, diagnosed between January 2006 and December 2022, where multimodality management, including perioperative chemotherapy, neoadjuvant chemoradiation, and surgery, plays a pivotal role. Exclusion criteria included non‐adenocarcinoma histology, prior malignancy, palliative surgery, carcinoma in situ, T1 disease, metastatic disease, and treatment records with unverifiable modality/classification. Variables Demographic variables included age at diagnosis, sex, race, and ethnicity. Age at diagnosis was stratified into three age groups: ≤ 45 years (EOGC), 46–69, and ≥ 70 years. Race and ethnicity were defined as Black; Asian/Pacific Islander (including East Asian, South Asian, or Pacific Islander); Hispanic; White; and Other/unknown. Clinical parameters included Charlson‐Deyo Comorbidity Index score [16], histologic subtype, tumor grade, primary tumor site, number of positive lymph nodes (LN), and pathologic stage [17]. Treatment‐related variables included definitive treatment category (neoadjuvant chemotherapy (CT), neoadjuvant chemoradiation therapy (CRT), adjuvant CT, adjuvant CRT, Perioperative CT, or Surgery alone), LN dissection type (degree [D] 0 vs. D1 vs. D2 vs. D2 > 25 LN removed) [18]. Treatment variables included receipt and type of CT (neoadjuvant, adjuvant, perioperative), radiotherapy, and surgical resection. Education level, income, and insurance type were also stratified across the three groups in this cohort. Outcomes Overall survival (OS) was the primary outcome measure, stratified by age group. Multivariable Cox proportional hazards models were used to adjust for clinicopathologic covariates and estimate hazard ratios (HRs) of death by age group. Statistical Analysis Clinicodemographic and pathologic variables were compared using the χ2 test. Univariate and multivariate Cox proportional hazards regression analyses were performed to evaluate associations with OS. Variables with p < 0.05 on the univariate model that had more than 20 events per variable were included in the multivariate model. Time zero was defined as the date of diagnosis recorded in the dataset. To mitigate survivorship and immortal time bias, we performed a 6‐month landmark survival analysis excluding patients with fewer than 6 months of follow‐up. This approach restricted the analysis to patients with sufficient follow‐up to reasonably receive intended multimodality therapy (e.g., neoadjuvant chemotherapy ± radiation or perioperative chemotherapy). Median follow‐up time was calculated using the Schemper and Smith method [19]. All analyses were conducted using R, version 4.1.2 (R Project for Statistical Computing). All tests were 2‐sided with p < 0.05 as the threshold for significance. Results Patient Characteristics In our cohort, most resectable stage II–III GC cases were diagnosed between ages 50 and 65, consistent with the typical age range for average‐onset disease. Incidence increased after age 45, peaked between 55 and 69, and declined after age 75. Among 26,267 patients, there was a total of 1943 patients under ≤ 45 years of age, comprising 7.3% of the total resected stage 2–3 GC population. OS analysis included 23,933 patients with available survival data from the overall study cohort of 26,267 eligible patients. Survival outcomes for EOGC were available for 766 of 813 patients included in the survival analysis. The overall age distribution among 26,267 patients with GC revealed that most cases occurred between 46 and 69 (60.5%) (Figure 1). Males predominated in the overall cohort (71.7%) and in patients ≤ 45 years old (62.4%) (Table 1). Age Distribution at Diagnosis of Stage II–III Resected Gastric Cancer. Distribution of patient age at diagnosis for stage II–III gastric cancer undergoing curative resection (N = 25,363). Green bars indicate patients aged ≤ 45 years; blue bars indicate patients aged 46–69 years. Percentages shown above represent the proportion of the total cohort in each age group. TABLE 1Baseline demographic and clinical characteristics of patients by age group.Variable≤ 45 Years (n = 1943)46–69 Years (n = 15,927)≥ 70 Years (n = 8,397)Total Cohort (N = 26,267) p‐valueSex, n (%)< 0.001Male1,212 (62.4)11,866 (74.5)5,758 (68.6)18,836 (71.7)Female731 (37.6)4,061 (25.5)2,639 (31.4)7,431 (28.3)Race, n (%)< 0.001White960 (49.4)10,912 (68.5)5,918 (70.5)17,790 (67.7)Black276 (14.2)1,890 (11.9)838 (10.0)3,004 (11.4)Hispanic462 (23.8)1,611 (10.1)766 (9.1)2,839 (10.8)Asian198 (10.2)1,166 (7.3)731 (8.7)2,095 (8.0)Other47 (2.4)348 (2.2)144 (1.7)539 (2.1)Comorbidity Score, n (%)< 0.00101,637 (84.3)11,421 (71.7)5,379 (64.1)18,437 (70.2)1251 (12.9)3,241 (20.3)1,953 (23.3)5,445 (20.7)255 (2.8)1,265 (7.9)1,065 (12.7)2,385 (9.1)Insurance Status, n (%)< 0.001Private1,290 (66.4)8,751 (54.9)907 (10.8)10,948 (41.7)Medicare64 (3.3)4,491 (28.2)6,993 (83.3)11,548 (44.0)Medicaid382 (19.7)1,599 (10.0)218 (2.6)2,199 (8.4)Other Government20 (1.0)287 (1.8)87 (1.0)394 (1.5)Uninsured148 (7.6)591 (3.7)81 (1.0)820 (3.1)Unknown39 (2.0)208 (1.3)111 (1.3)358 (1.4)Income Quartile, n (%)0.0021. <$38 K333 (17.1)2,308 (14.5)1,161 (13.8)3,802 (14.5)2. $38 K–48 K387 (19.9)3,162 (19.9)1,562 (18.6)5,111 (19.5)3. $48 K–63 K453 (23.3)3,764 (23.6)2,023 (24.1)6,240 (23.8)4. >$63 K541 (27.8)4,640 (29.1)2,537 (30.2)7,718 (29.4)Unknown229 (11.8)2,053 (12.9)1,114 (13.3)3,396 (12.9)Education Level, n (%)< 0.0011. > 21% (Low Ed)420 (21.6)2,666 (16.7)1,307 (15.6)4,393 (16.7)2.13%–21%471 (24.2)3,618 (22.7)1,849 (22.0)5,938 (22.6)3.7%–12.9%487 (25.1)4,438 (27.9)2,398 (28.6)7,323 (27.9)4. < 7% (High Ed)336 (17.3)3,159 (19.8)1,733 (20.6)5,228 (19.9)Unknown229 (11.8)2,046 (12.8)1,110 (13.2)3,385 (12.9)Geographic Location, n (%)< 0.001East North Central177 (16.1)2,865 (18.0)1,399 (16.7)4441 (16.9)Middle Atlantic209 (19.0)2,760 (17.3)1,701 (20.3)4,670 (17.8)Pacific173 (15.7)2,129 (13.4)1,244 (14.8)3,546 (13.5)South Atlantic233 (21.2)3,214 (20.2)1,680 (20.0)5,127 (19.5)West South Central104 (9.5)1,270 (8.0)637 (7.6)2,011 (7.7)West North Central65 (5.9)1,235 (7.8)526 (6.3)1,826 (7.0)New England53 (4.8)960 (6.0)524 (6.2)1,537 (5.9)East South Central39 (3.5)842 (5.3)353 (4.2)1,234 (4.7)Mountain47 (4.3)652 (4.1)333 (4.0)1,032 (3.9)Abbreviations: Govt, government; High Ed, high school graduation rate > 93% in the patient's zip code; Low Ed, high school graduation rate < 79% in the patient's zip code; Score, Charlson–Deyo Comorbidity Index p‐values represent the differences across age cohorts calculated via chi‐square analysis. Baseline demographic and clinical characteristics of patients by age group. Abbreviations: Govt, government; High Ed, high school graduation rate > 93% in the patient's zip code; Low Ed, high school graduation rate < 79% in the patient's zip code; Score, Charlson–Deyo Comorbidity Index p‐values represent the differences across age cohorts calculated via chi‐square analysis. Tumor Characteristics Across the overall cohort, the most common primary tumor site was the cardia (52.1%), followed by body (22%) and antrum (14.7%). The category of body also encompassed tumors of the greater curvature, lesser curvature, and overlapping lesions. In EOGC, cardia tumors were the most frequent primary site (42.2%), exceeding the proportions of antral (18.3%) and body tumors (26.5%), although they did not constitute the majority (p < 0.001) (Table 2). Overall, cardia tumors were also the most common site in the entire cohort (52.1%), with a marked predominance in patients aged 46–69 years (58.0%), compared with 42.2% in those ≤ 45 years and 43.3% in those ≥ 70 years. In contrast, antral tumors were less frequent overall (14.7%) and demonstrated a different distribution pattern, with comparable proportions in younger (18.3%) and older patients (18.8%) but a lower prevalence in the middle‐aged group (12.1%). Collectively, these findings highlight an age‐related shift in tumor location, characterized by a predominance of cardia tumors in middle‐aged patients and relatively higher proportions of antral and body tumors at younger and older ages. When stratified by age, diffuse‐type histology including signet ring features was observed in 19.9% of the overall cohort and 37.9% of the EOGC cohort (Table 2). TABLE 2Patient treatment modalities and summaries stratified by age at diagnosis.Variable≤ 45 Years (n = 1943)46–69 Years (n = 15,927)≥ 70 Years (n = 8,397)Total Cohort (N = 26,267) p‐valuePrimary Tumor Site, n (%)< 0.001Cardia819 (42.2)9,236 (58.0)3,633 (43.3)13,688 (52.1)Antrum355 (18.3)1,924 (12.1)1,582 (18.8)3,861 (14.7)Body515 (26.5)3,163 (19.9)2,112 (25.2)5,790 (22.0)Fundus42 (2.2)358 (2.2)225 (2.7)625 (2.4)Pylorus56 (2.9)328 (2.1)225 (2.7)609 (2.3)Unknown156 (8.0)918 (5.8)620 (7.4)1,694 (6.4)Histology, n (%)< 0.001Signet Cell/Diffuse736 (37.9)3,141 (19.7)1,350 (16.1)5,227 (19.9)Non‐Signet/Diffuse1,207 (62.1)12,786 (80.3)7,047 (83.9)21,040 (80.1)Tumor Grade, n (%)< 0.001Poorly Differentiated988 (50.8)6,806 (42.7)3,489 (41.6)11,283 (43.0)Moderately Diff.237 (12.2)2,934 (18.4)1,653 (19.7)4,824 (18.4)Well Differentiated29 (1.5)326 (2.0)198 (2.4)553 (2.1)Unknown Grade689 (35.5)5,861 (36.8)3,057 (36.4)9,607 (36.6)Treatment Modality, n (%)< 0.001Neoadjuvant CT or CT/RT822 (42.3)8,568 (53.8)3,689 (43.9)13,079 (49.8)Perioperative CT558 (28.7)3,281 (20.6)1,179 (14.0)5,018 (19.1)Adjuvant CT or CRT387 (19.9)2,357 (14.8)1,277 (15.2)4,021 (15.3)Surgery Only96 (4.9)1127 (7.1)2,022 (24.1)3,245 (12.4)Surgical Dissection, n (%)< 0.001D043 (2.2)443 (2.8)250 (3.0)736 (2.8)D1583 (30.0)5,884 (36.9)3,236 (38.5)9,703 (36.9)D2692 (35.6)5,411 (34.0)2,770 (33.0)8,873 (33.8)D2 > 25 Nodes625 (32.2)4,189 (26.3)2,141 (25.5)6,955 (26.5)Surgical Margins, n (%)< 0.001Negative1,550 (79.8)13,743 (86.3)7,243 (86.3)22,536 (85.8)Positive356 (18.3)1,862 (11.7)987 (11.8)3,205 (12.2)Unknown37 (1.9)322 (2.0)167 (2.0)526 (2.0)Abbreviations: CRT, chemoradiotherapy; CT, chemotherapy; D0, no lymph node dissection or < 10 nodes examined; D1, 10–15 nodes examined; D2, 16–25 nodes examined (formal lymphadenectomy); D2 > 25, > 25 nodes examined (high‐yield dissection); Diff, differentiated; RT, radiation therapy. Patient treatment modalities and summaries stratified by age at diagnosis. Abbreviations: CRT, chemoradiotherapy; CT, chemotherapy; D0, no lymph node dissection or < 10 nodes examined; D1, 10–15 nodes examined; D2, 16–25 nodes examined (formal lymphadenectomy); D2 > 25, > 25 nodes examined (high‐yield dissection); Diff, differentiated; RT, radiation therapy. Treatment Modalities Treatment strategies varied significantly across age groups (p < 0.001). Among EOGC patients, multimodality treatment was more frequently administered. Specifically, perioperative chemotherapy was used in 28.7% of EOGC patients and 20.6% of those aged 46–69 years, and 14% in those aged ≥ 70 years (Table 2, p < 0.001). Similarly, adjuvant chemoradiation was more common in younger cohorts (19.9% for ≤ 45 years vs. 15.3% for ≥ 70 years). In contrast, surgery alone was more common in older patients, used in 24.8% of those aged ≥ 70 years compared with only 5.2% of EOGC patients (Table 2). Multimodality treatment, particularly perioperative therapy, was predominantly used in EOGC. Among patients with EOGC, multivariable analysis identified diffuse type (including signet ring histology), positive surgical margin, lymphovascular invasion, and higher nodal burden as independent predictors of inferior OS. Specifically, diffuse‐type histology (HR 1.42, p = 0.003), positive margin (HR 1.87, p < 0.001), and ≥ 4 positive LN (HR 3.16, p < 0.001) were strongly associated with poor outcomes. Extent of LN dissection and treatment modality were not significantly correlated with survival in this young cohort. Demographic and Sociological Differences in EOGC Demographic and socioeconomic profiles were distinct within the EOGC population. Hispanic patients represented 23.8% of the EOGC group (p < 0.001), while Black patients accounted for 14.2% (p < 0.001), White patients represented 49.4%, and individuals of Asian descent made up 10.2% (p < 0.001) (Table 1). A greater proportion of EOGC patients resided in areas with a median household income <$38,000 (17.1%; p = 0.025). This choropleth map illustrates the proportion of EOGC as a percentage of all patients within each U.S. Census division, with darker red shades indicating higher regional representation. Socioeconomically, the ≤ 45 group faced greater disparities. They were more frequently uninsured (7.6%) or reliant on Medicaid (19.7%), and they represented the highest proportion of residents from areas with the lowest educational attainment (21.6%). Conversely, they were the healthiest group clinically, with 84.3% having a Charlson–Deyo Comorbidity Score of 0 (Table 1). As shown in Figure 2, the color intensity reflects the proportion of patients aged ≤ 45 years across U.S. regions; warmer colors indicate a higher percentage of early‐onset cases, demonstrating substantial geographic heterogeneity with relative enrichment in the South, Southwest, California, Texas, and Alaska, and lower proportions in parts of the Midwest and Northeast. Geographic distribution of patients aged ≤ 45 years with gastric cancer across U.S. Census Divisions. This U.S. map illustrates the geographic distribution of patients aged ≤ 45 years with gastric cancer as a percentage of all patients, stratified by U.S. Census Division. Warmer colors indicate a higher percentage of early‐onset cases, demonstrating substantial geographic heterogeneity with relative enrichment in the South, Southwest, California, Texas, and Alaska, and lower proportions in parts of the Midwest and Northeast. Other regions included: East North Central, East South Central, Middle Atlantic, Mountain, New England, Pacific, South Atlantic, and West North Central. For patients aged ≤ 45 years, the South Atlantic region accounted for the largest proportion of cases at 21.2% (n = 233). This was followed by the Middle Atlantic (19.0%, n = 209) and East North Central (16.1%, n = 177) regions. Notably, the EOGC cohort showed a higher relative concentration in the Pacific region (15.7%) compared to the 46–69 age group (13.4%). Conversely, the East South‐Central region represented the smallest geographic footprint for the EOGC group, containing only 3.5% (n = 39) of these patients. Among EOGC, Hispanic and Black individuals represented disproportionately higher shares relative to their overall cohort sizes. Specifically, 16.3% of Hispanic and 9.2% of Black GC cases occurred before age 45, compared with only 5.4% of White patients. In contrast, the White population comprised most late‐onset cases (aged 70 or older). These data highlight a younger age distribution among minority populations, particularly Hispanics (Table S1). Survival Outcomes and Follow‐Up Among 23,933 patients with stage II–III gastric adenocarcinoma, OS differed significantly by age at diagnosis. In the EOGC cohort, OS demonstrated a gradual but sustained decline over time. The OS was 49.8 months (95% CI: 45.0–56.0), with a 36‐month OS rate of 58.3% (95% CI: 55.9%–60.7%). Median follow‐up was 60.0 months (IQR: 48.8–60.0), providing robust long‐term outcome assessment (Figure 3). Patients with EOGC had overall survival comparable to that of patients aged ≤ 65 years but superior to that of patients aged ≥ 66 years, with the greatest survival observed compared with patients aged ≥ 76 years. Survival progressively declined in older age groups, with median OS of 39.7 months (95% CI, 37.8–41.5) for patients aged 66–75 years and 28.6 months (95% CI, 26.9–30.4) for those aged ≥ 76 years. The 36‐month OS rate was lowest among patients aged ≥ 76 years (44.3%). Overall Survival by Age at Diagnosis Among Patients with Stage II–III Gastric Adenocarcinoma. Kaplan–Meier curves demonstrate overall survival stratified by age groups (≤ 45, 46–55, 56–65, 66–75, and ≥ 76 years). Younger and middle‐aged patients (≤ 65 years) show comparable survival outcomes, whereas patients aged ≥ 66 years, particularly those ≥ 76 years, exhibit progressively worse survival. Median overall survival decreased with increasing age, from approximately 49.8 months in patients ≤ 45 years to 28.6 months in those ≥ 76 years. Similarly, 36‐month overall survival declined across age groups (58.3% in ≤ 45 years vs. 44.3% in ≥ 76 years). The number at risk at selected time points is shown below the x‐axis. Discussion In this large national cohort of patients with stage II–III GC treated with curative intent, individuals with EOGC demonstrated distinct clinical, sociodemographic, and pathologic features. These differences underscore the multifactorial nature of EOGC and highlight the need to address both tumor‐associated features and broader social determinants of health, particularly as EOGC incidence continues to rise [20, 21]. Recent studies have reported a rising incidence of non‐cardia GC in younger individuals, particularly in historically low‐incidence countries. Proposed contributors include altered gastric microbiota and the increasing prevalence of autoimmune disorders [22, 23]. Consistent with prior reports, EOGC in our cohort demonstrated a strong male predominance, with an approximately 2:1 male‐to‐female ratio. Histologically, younger patients exhibited a striking enrichment of signet ring cell and diffuse‐type adenocarcinoma, accounting for nearly one‐third of cases. The convergence of male predominance, aggressive histology, and advanced stage at presentation highlights a distinct clinical phenotype that differentiates EOGC from later‐onset GC and challenges assumptions that younger age confers biologic or prognostic advantage. Despite the more aggressive clinicopathologic features of EOGC, OS was comparable to younger non‐EOGC patients (< 65 years) but superior to patients aged ≥ 65 years, likely reflecting differences in age‐related comorbidities, treatment tolerance, and competing mortality [17, 24, 25, 26]. Cardia gastric cancers have been reported to occur more commonly in White patients, whereas non‐cardia (distal) tumors are more prevalent in other racial and ethnic groups [27]. Multiple studies show that cardia tumors often have worse outcomes, with cardia cancer associated with lower overall survival and disease‐free survival [28]. In our cohort, cardia tumors were the most common site in younger patients, although they did not constitute the majority, and their distribution varied significantly across age groups. These patterns are consistent with distinct etiologic pathways, as prior studies have linked cardia tumors to gastroesophageal reflux and dietary factors, whereas non‐cardia tumors are more strongly associated with Helicobacter pylori infection [29]. Histopathologic differences further support this distinction, as non‐cardia tumors have been shown to exhibit higher rates of poorly differentiated and signet‐ring cell histology, features associated with more aggressive tumor biology. Differences in racial distribution and survival between cardia and non‐cardia cancers have also been reported, with cardia tumors more common in White patients and often associated with worse outcomes. Together, these observations support the concept that cardia and antral EOGC may represent distinct clinical subtypes, although this should be interpreted cautiously given the limitations of registry‐based data [30, 31]. While these treatment patterns may reflect recognition of younger patients' greater functional reserve and treatment tolerance, EOGC was associated with lower rates of pathologic complete response, more frequent upstaging at surgery, and higher rates of positive margins. Together, these findings suggest that EOGC may represent a clinically aggressive and distinct entity with a more aggressive phenotype. Prior studies support this observation. Zhou et al. reported that GC patients aged ≤ 30 years presented with poor differentiation, advanced stage, and inferior prognosis [32] while Zhao et al. found no survival benefit despite more extensive LN dissection in younger patients (< 40 years old) when compared to patients > 40 years old [33]. Higher peritoneal recurrence has also been reported in younger cohorts (< 49 years old) with worse 5‐year OS [34]. Emerging data suggest that gastric microbiome alterations, including dysbiosis beyond Helicobacter pylori , contribute to gastric carcinogenesis through modulation of local inflammation and immune responses [35]. Furthermore, autoimmune atrophic gastritis, a chronic immune‐mediated condition, alters gastric acidity and microbiota composition and is associated with increased gastric carcinoma risk, potentially providing a biological substrate for unique tumor subtypes. Signet‐ring/diffuse histology represents a highly aggressive phenotype; although direct microbiome–histology correlations are not yet fully established, these mechanistic pathways support investigation of microbiome and immune dysregulation as contributors to EOGC biology [36, 37]. The addition of durvalumab to perioperative FLOT (5‐fluorouracil, leucovorin, oxaliplatin, and docetaxel) has improved event‐free survival and pathologic complete response in resectable, locally advanced gastric and gastroesophageal junction adenocarcinoma, establishing a new benchmark for multimodality therapy [19]. However, the benefit appeared attenuated in diffuse‐type tumors, suggesting that intrinsic tumor biology influences immunotherapy responsiveness [19]. Further studies integrating molecular profiling, immune characterization, and treatment response are warranted to identify predictive biomarkers and optimize therapeutic strategies for diffuse/poorly cohesive EOGC. Geographic and institutional factors may contribute to the distinct care patterns observed among EOGC. This cohort revealed a geographic clustering of EOGC cases, with disproportionate representation in states such as Texas, California, Alaska, and Hawaii, and urban and coastal areas with more racially and ethnically diverse populations. These regions overlap substantially with areas of higher foreign‐born populations, suggesting that immigration‐linked exposures, early‐life environmental factors, dietary patterns, Helicobacter pylori prevalence, and barriers to preventive healthcare may contribute to disease risk. This regional enrichment underscores the limitation of uniform national screening approaches and supports the need for geographically and demographically informed strategies. Importantly, the observed 7% prevalence of EOGC appears to reflect true national epidemiology rather than institutional or referral bias, reinforcing the generalizability of our findings. Accordingly, geographic clustering of EOGC may reflect broader demographic and environmental determinants rather than differences in treatment delivery. For example, a Texas‐based epidemiologic analysis of H. pylori seropositivity reported prevalence rates of 30.3% among Hispanic men vs. 9.2% among non‐Hispanic white men (n = 284) [38]. Previous national studies have reported H. pylori seropositivity rates exceeding 40% in some southern U.S. populations [38] and approximately 57% among Mexican Americans in Texas [39]. The NCDB lacks population‐level data on immigration history and neighborhood context, limiting adjustment for these factors. Observed differences are correlative rather than causal, although they align with patterns of EOGC prevalence among immigrant and non‐White populations [20, 40]. Emerging data have suggested EOGC may harbor a distinct genomic landscape, featuring enriched somatic alterations such as CDH1 mutations, which are commonly linked to diffuse‐type histology and poor prognosis [12]. While TP53 mutations appear common across both early‐ and late‐onset gastric cancer, their co‐occurrence with CDH1 mutations in younger patients may define particularly aggressive subtypes [12]. One study investigating the somatic landscape of EOGC found that CDH1 mutations and FGFR2 copy number gains were enriched among younger patients [32]. Mutations in DNA repair pathways, chromatin remodeling genes, and epigenetic regulators have been reported in exploratory studies of EOGC [12, 41]. Recent studies suggest that hub genes and EOGC‐specific alternative splicing events are associated with distinct immune cell landscapes in EOGC, potentially modulating key pathways involved in tumor growth and proliferation [42]. These studies suggest that intrinsic molecular programs, beyond environmental factors, may underlie the distinct behavior of EOGC observed in this study. Limitations This study has several limitations. As a retrospective analysis of a national database, results are subject to coding errors, unmeasured confounders, and missing data. Although the NCDB is one of the most comprehensive and rigorously audited cancer registries in the United States, capturing approximately 70% of newly diagnosed malignancies, it lacks key variables such as disease recurrence, cause‐specific mortality, MSI or EBV status, and other genomic features, limiting biologic interpretation. Detailed information on chemotherapy regimens, timing, and adherence is also unavailable, and data completeness may vary across institutions and reporting periods. In the EOGC subgroup, additional HIPAA‐related masking of geographic and ZIP code–level variables restricts analyses of social determinants of health. Despite these limitations, this large national cohort provides substantial statistical power and offers valuable real‐world insight into demographic, tumor, and treatment patterns in early‐onset GC in the United States [15]. A substantial proportion of cases had unknown tumor grade, which introduces potential information bias and limits the interpretability of grade‐stratified analyses. Therefore, findings related to tumor differentiation should be interpreted with caution, although prior literature supports the relevance of poorly differentiated and signet‐ring histology in EOGC. Future Direction Prospective studies integrating molecular, genomic, sociodemographic, and health‐system–level data are needed to clarify the drivers of early‐onset GC. Such work may identify populations at highest risk for EOGC and inform targeted screening, prevention, and early detection strategies. Future efforts should prioritize regionally informed and age‐targeted early detection strategies, alongside integration of molecular profiling and social determinants of health, to better define disease heterogeneity and improve outcomes for younger patients with gastric cancer. Conclusion Although EOGC comprises only 7.3% of all GC cases, this proportion reflects true national epidemiology, and our cohort of ~2,000 young patients represents one of the largest U.S. datasets available to meaningfully characterize this clinically distinct population. EOGC demonstrated regional enrichment, particularly in areas with a higher census of foreign‐born populations. Our findings indicate that EOGC represents a socio‐demographically distinct subset of patients who often present with signet ring cell and diffuse histology and advanced nodal disease. Despite receiving more intensive multimodality treatment, younger patients did not experience superior survival outcomes, suggesting that treatment intensification alone is insufficient to overcome adverse tumor biology and late presentation. These findings suggest that differences in outcomes may be driven more by a combination of aggressive histologic subtype distribution, delayed diagnosis, and healthcare‐related factors rather than therapeutic underutilization. Author Contributions Mengni Guo: investigation, writing – original draft, writing – review and editing, methodology. Pranati Shah: conceptualization, writing – original draft, writing – review and editing, validation. Derek Tai: writing – original draft, writing – review and editing, validation. Yan Xing: writing – original draft, writing – review and editing, validation. Max Hazeltine: validation, writing – review and editing. Mustafa Raoof: writing – original draft, writing – review and editing, resources. Daniel Park: writing – original draft, writing – review and editing. Cathy Eng: conceptualization, supervision, investigation. Sofia Guzman: project administration, data curation, writing – review and editing, writing – original draft. Gagandeep Brar: writing – original draft, writing – review and editing, conceptualization. Dani R. Castillo: conceptualization, writing – original draft, writing – review and editing, methodology, formal analysis, supervision. Shengyang Wu: conceptualization, methodology, software, formal analysis, investigation, writing – original draft, writing – review and editing. Rifat Mannan: writing – original draft, conceptualization, writing – review and editing. Funding No external funding was obtained for this study. Disclosure IRB Statement: Institutional review board approval was not required as the NCDB PUF contains de‐identified patient information and is provided to investigators under a data use agreement, exempting it from human subjects' review. Ethics Statement Ethical approval was not required because the NCDB Participant User File contains fully de‐identified data and is provided under a data use agreement. Consent Patient consent was waived as the study used de‐identified, retrospective data from the NCDB. Conflicts of Interest D.R.C. reports personal consulting fees from Amgen, BeOne, Daiichi Sankyo, and Guardant Health. All other authors declare no competing interests. Supporting information Table S1: Racial and Ethnic Distribution of Patients with Stage II–III Gastric Cancer, Stratified by Age at Diagnosis.